Sphingosomal vincristine in CHOP +/- rituximab is a promising new treatment for patients with high risk untreated aggressive non-hodgkin's lymphoma (NHL): Follow-up results of a phase II study.

被引：0
|
作者：
Rodriguez, MA [1 ]
Sarris, A [1 ]
Dang, NH [1 ]
Fayad, L [1 ]
Goy, A [1 ]
Hagemeister, F [1 ]
McLaughlin, P [1 ]
Pro, B [1 ]
Romaguera, J [1 ]
Samaniego, F [1 ]
Younes, A [1 ]
Cabanillas, F [1 ]
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4620
引用
收藏
页码：234B / 234B
页数：1
相关论文
共 50 条
  • [1] Sphingosomal vincristine in chop ± rituximab:: A promising new treatment for patients with high risk untreated aggressive non-Hodgkin's lymphoma (NHL)
    Rodriguez, M
    Sarris, A
    Dang, N
    [J]. ANNALS OF ONCOLOGY, 2005, 16 : 209 - 209
  • [2] Phase II study of sphingosomal vincristine in CHOP± rituximab for patients with aggressive non-Hodgkin's lymphoma (NHL):: Promising 3 year follow-up results in elderly patients
    Rodriguez, MA
    Dung, NH
    Fayad, L
    Goy, A
    Hagemeister, F
    McLaughlin, P
    Pro, B
    Romaguera, J
    Younes, A
    Cabanillas, F
    [J]. BLOOD, 2005, 106 (11) : 277A - 277A
  • [3] Sphingosomal vincristine in CHOP is a promising new treatment for elderly, as well as poor prognosis patients with aggressive non-Hodgkin's lymphoma (NHL): Follow-up results of a phase II study
    Rodriguez, MA
    Dang, NH
    Fayad, L
    Goy, A
    Hagemeister, FB
    McLaughlin, P
    Pro, B
    Romaguera, JE
    Younes, A
    Cabanillas, F
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 748S - 748S
  • [4] Long term follow-up of a phase II study of Rituximab in combination with CHOP chemotherapy in patients with previously untreated aggressive non-Hodgkin's lymphoma (NHL).
    Vose, JM
    Link, BK
    Grossbard, ML
    Czuczman, M
    Grillo-Lopez, A
    Benyunes, M
    Gaynor, E
    Fisher, RI
    [J]. BLOOD, 2002, 100 (11) : 361A - 361A
  • [5] A phase II study of liposomal vincristine in CHOP with rituximab for patients with untreated aggressive B-cell non-Hodgkin's lymphoma (NHL): A safe and effective combination.
    Rodriguez, MA
    Sarris, A
    East, K
    Dang, NH
    Fayad, L
    Goy, A
    Hagemeister, FB
    McLaughlin, P
    Pro, B
    Romaguera, J
    Samaniego, F
    Younes, A
    Cabanillas, F
    [J]. BLOOD, 2002, 100 (11) : 92A - 92A
  • [6] Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
    Vose, JM
    Link, BK
    Grossbard, ML
    Czuczman, M
    Grillo-Lopez, A
    Gilman, P
    Lowe, A
    Kunkel, LA
    Fisher, RI
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) : 389 - 397
  • [7] Phase II study of rituximab in combination with CHOP chemotherapy and GMCSF in patients with previously untreated aggressive non-Hodgkin's lymphoma.
    Venugopal, P
    Gregory, SA
    Wooldridge, J
    Yunus, F
    Adler, S
    Shammo, J
    Enschede, S
    O'Brien, T
    Franson, P
    Porter, C
    [J]. BLOOD, 2002, 100 (11) : 314B - 314B
  • [8] Rituximab plus CHOP followed by maintenance rituximab as initial therapy for aggressive non-Hodgkin's lymphoma (NHL); Initial results of induction therapy, including rituximab pharmacokinetics, in a phase II study.
    Huang, JE
    Saleh, A
    Lee, JT
    Langmuir, V
    Zhang, F
    Hainsworth, J
    [J]. BLOOD, 2004, 104 (11) : 238B - 238B
  • [9] Multiply relapsed diffuse, aggressive non-Hodgkin's lymphoma (NHL) patients respond to single agent sphingosomal vincristine
    Winter, JN
    [J]. BLOOD, 2003, 102 (11) : 638A - 638A
  • [10] CHOP combined with amifostine (AMI-CHOP) in the treatment of elderly patients with aggressive non-Hodgkin's lymphomas (NHL) -: A phase II study.
    Späth-Schwalbe, E
    Lange, C
    Genvresse, I
    Sezer, O
    Eucker, J
    Possinger, K
    [J]. BLOOD, 2000, 96 (11) : 249B - 249B
12345